Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

31.42 -0.83 (-2.57%)
Streaming Delayed Price Updated: 11:40 AM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Genmab Reports Mixed Results From Late-Stage Trial Of Lymphoma Drug ↗
Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma, the company said. 
Via Stocktwits
News headline image
Why Are Investors Paying Attention To Genmab Stock? ↗
Shares of Genmab (NASDAQ: GMAB) are rising Wednesday after the Danish biotechnology company said it would partner with AI company Anthropic. 
Via Benzinga
Topics Artificial Intelligence
GENMAB A/S -SP ADR (NASDAQ:GMAB) Passes Peter Lynch's GARP Investment Screen ↗
Via Chartmill
News headline image
Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech ↗
The company has decided to concentrate on cancer therapies Epkinly, Petosemtamab and Rina‑S, which are in late-stage development. 
Via Stocktwits
Topics Supply Chain
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
Analyst Expectations For Genmab's Future ↗
 
Via Benzinga
News headline image
Genmab (GMAB) Q3 2025 Earnings Call Transcript ↗
Genmab (GMAB) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer ↗
Genmab's Epkinly receives traditional FDA approval for relapsed or refractory follicular lymphoma in combination and monotherapy. Clinical trial data show superior results. 
Via Benzinga
News headline image
Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? ↗
Halozyme also boasts a 98 Composite Rating out of 99. The best growth stocks have a Composite of 90 or better. 
Via Investor's Business Daily
News headline image
Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
Why Is Genmab Stock Trading Lower On Monday? ↗
Genmab reported a 50% response rate and durable results for Rina-S in advanced endometrial cancer, with manageable side effects and no major toxicities. 
Via Benzinga
News headline image
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Genmab Stock Popped on Friday ↗
Two pundits raised their price targets on the company. 
Via The Motley Fool
News headline image
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
Why Genmab Stock Was Marching Higher Today ↗
The company's latest asset purchase seems to be impressing analysts. 
Via The Motley Fool
News headline image
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
News headline image
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough ↗
Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. 
Via Benzinga
News headline image
Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus ↗
The takeover candidate is working on a bispecific antibody, capable of simultaneously blocking two drivers of cancer. 
Via Investor's Business Daily
Topics Government
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB) Meets Peter Lynch's GARP Investment Criteria ↗
Discover GMAB, a biotech stock matching Peter Lynch's GARP strategy. It offers strong earnings growth, a low PEG ratio, and excellent financial health for long-term investors. 
Via Chartmill
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB): A High-Value Biotech Play with Strong Fundamentals ↗
Genmab (GMAB) is a high-value biotech stock with a low P/E ratio, strong financial health, and robust profitability, making it a standout undervalued opportunity. 
Via Chartmill
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB): An Affordable Growth Candidate in Biotechnology ↗
Discover GENMAB A/S (GMAB), an affordable growth stock with strong revenue expansion, solid profitability, and a reasonable valuation in the biotech sector. 
Via Chartmill
News headline image
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% ↗
Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat. 
Via Benzinga
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Biotech Stock With Strong Growth and Reasonable Valuation ↗
GENMAB A/S (NASDAQ:GMAB) is a biotech stock with strong earnings growth, high profitability, and a reasonable valuation, making it a candidate for long-term investors following Peter Lynch's strategy. 
Via Chartmill
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Candidate for GARP Investors ↗
GENMAB A/S (NASDAQ:GMAB) offers strong earnings growth, high profitability, and an attractive valuation, making it a solid pick for GARP investors following Peter Lynch's strategy. 
Via Chartmill
News headline image
Why Genmab Stock Smashed It on Monday ↗
Via The Motley Fool
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Growth Stock Showing Technical Breakout Potential ↗
GENMAB A/S (NASDAQ:GMAB) is a strong growth stock with solid fundamentals and a promising technical breakout pattern, offering potential for investors seeking growth opportunities. 
Via Chartmill
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for Affordable Growth Investors ↗
GENMAB A/S (NASDAQ:GMAB) offers strong growth, solid profitability, and attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector. 
Via Chartmill
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for GARP Investors ↗
GENMAB A/S (NASDAQ:GMAB) offers strong growth, profitability, and a reasonable valuation, making it a standout pick for GARP investors following Peter Lynch’s strategy. 
Via Chartmill
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals. ↗
GENMAB A/S -SP ADR is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:GMAB showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB): A Strong Affordable Growth Stock ↗
GENMAB A/S -SP ADR (NASDAQ:GMAB): A Strong Affordable Growth Stock 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.